Sublicense Income. Tarsus shall pay Elanco a percentage of all Sublicense Revenue. The percentage of such Sublicense Revenue that shall be paid to Elanco shall be as follows: (a) Until first dosing of a Licensed Product in a [***]: [***]%; (b) After first dosing of a Licensed Product in a [***] until first dosing of a [***]: [***]%; (c) After first dosing of a Licensed Product in a [***] until first [***] of a Licensed Product: [***]%; or (d) After first [***] of a Licensed Product and thereafter: [***]%. For clarity, and without limitation, none of the following shall be deemed Sublicense Revenue: [***]
Appears in 4 contracts
Samples: License Agreement (Tarsus Pharmaceuticals, Inc.), License Agreement (Tarsus Pharmaceuticals, Inc.), License Agreement (Tarsus Pharmaceuticals, Inc.)
